To define the alteration of sensitivity of cancer cells to one of the EGFR inhibitors, gefitinib, in response to the methionine depletion, we started with the assessment of EGFR mRNA level in H1299 and SK-BR-3 cells treated with MGL S3 and MGL tetani for 48 h. This evidence concerns the gene EGFR and cancer.